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Nasopharyngeal carcinoma (NPC) is a rare malignancy in most parts of the world, but is one of the most common cancers in
Southeast Asia. Both genetic and environmental factors contribute to the tumorigenesis of NPC, most notably the consumption
of certain salted food items and Epstein-Barr virus infection. This review will focus on the current progress of the genetic analysis
of NPC (genetic susceptibilities and somatic alterations). We will review the current advances in genomic technologies and their
shaping of the future direction of NPC research.
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1. INTRODUCTION TO NPC
The nasopharyngeal carcinoma (NPC) is a malignancy of
the head and neck region that arises from the epithelial cells
that cover the surface and line the nasopharynx. This dis-
ease was initially reported in 1901, and characterized clin-
ically in 1922 [1]. It is a rare malignancy in the United
States, accounting for 2% of all head and neck squamous
cell carcinomas, with an incidence of 0.5 to 2 per 100,000.
However, it is endemic in many geographical regions, in-
cluding Southern China and Southeast Asia, where the ob-
served incidence rates range from 15 and 50 per 100,000
persons. An intermediate incidence has been reported in
Alaskan Eskimos and in the Mediterranean basin (North
Africa, Southern Italy, Greece, and Turkey), ranging from
15 to 20 cases per 100,000 persons [2]. A male preponder-
ance exists; with a male-to-female ratio of approximately
2 : 1. Overall, NPC can occur in all age groups, but has a bi-
modal age distribution. The incidence peaks at 50 to 60 years
of age; and a small peak is observed during late childhood
[3].
1.1. Anatomy
The nasopharynx (the upper part of the throat, behind the
nose) is a cuboidal chamber (about 1.5 inches on each edge)
located posterior to the nasal choanae (see Figure 1). It is
bounded superiorly by the clivus, and inferiorly by the lower
border of the soft palate. The posterior border is made up by
the mucosa that overlies the superior constrictor muscles of
the pharynx and the prevertebral fascia of the C1 and C2 ver-
tebral bodies. Its lateral walls contain the Eustachian tubes’
orifices. The fossa of Rosenmu¨ller represents the most com-
mon site of origin for NPC [4].
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Figure 1: Anatomic site of NPC.
1.2. Epidemiology
In endemic regions, NPC presents as a complex dis-
ease caused by an interaction of the oncogenic gamma-
herpesvirus Epstein-Barr virus (EBV) chronic infection, en-
vironmental, and genetic factors, in a multistep carcinogenic
process. The EBV is spread worldwide, infecting over 95%
of the adult population [5]. It is transmitted by saliva and
its primary infection occurs during childhood with replica-
tion of the virus in the oropharyngeal lining cells, followed
by a latent infection of B lymphocytes (primary target of
the EBV). Although the infection is typically subclinical, the
virus is associated with later development of several malig-
nancies, including NPC [6]. Elevated titers of EBV associated
antigens (especially of IgA class), a latent EBV infection iden-
tified in neoplastic cells of virtually all cases of NPC, and the
clonal EBV genome consistently detected in invasive carcino-
mas and high-grade dysplastic lesions suggest a critical role
of EBV in the pathogenesis of NPC in endemic areas.
Significant environmental factors contribute to NPC in-
clude the consumption of foods high in salt, exposure to ni-
trosamines and polycyclic hydrocarbons as important car-
cinogens. In nonendemic areas, the association of NPC with
alcohol and tobacco use has been reported, either as weak or
controversial in some series [3, 7].
Genetic studies of endemic populations revealed the as-
sociation of HLA antigen haplotype with NPC: HLA-2, HLA-
B17, and HLA-Bw26 double the risk of the disease, and ge-
nomic and cytogenetic studies have shown multiple aberra-
tions in chromosomes 1, 3, 9, 11, 12, and 14. These genetic
factors will be discussed in association with the current ad-
vances in genomic technologies in the following sections.
1.3. Sign and symptoms
NPC may easily escape diagnosis at early stages, and most of
the cases remain undiagnosed until they present as a metas-
tasis to the lymph nodes of the neck. The tumor is difficult to
diagnose for multiple reasons including the nonspecificity of
the initial symptoms and the difficulty of examining the post-
nasal space. Additionally, lesions can grow within the submu-
cosa of the nasopharynx and escape endoscopic visualization
[8–10]. The majority of tumors arise in the lateral walls, es-
pecially from the fossa of Rosenmuller and Eustachian tube
cushions. Tumors can grow within the nasopharynx or ex-
tend to the opposite lateral wall; they can also infiltrate other
structures toward the base of the skull, and invade the palate,
nasal cavity, or the oropharynx. The most common present-
ing symptom is a painless cervical lymph node enlargement
due metastasis, followed by nasal, aural, and neurological
symptoms. A unilateral neck mass is reported in about 36%
of cases, but other series report rates as high as 80% [3].
Only 5% of cases reported in Southern China present with
distant metastases [2]. Enlargement and extension of the tu-
mor within the nasopharynx may cause nasal obstruction-
related symptoms such as congestion, nasal discharge, and
bleeding. Blockage of the Eustachian tube and/or extension
into the ear may result in changes in hearing or hearing loss
(usually unilateral). Extension of the tumor into the base of
the skull is usually associated with cranial nerve deficits. The
most common distal metastatic sites are bone, lung, medi-
astinum, and more rarely liver [11]. Symptoms related with
the distal metastatic disease include bone pain or organ dys-
function.
1.4. Pathology
With the constant advance in our understanding of this dis-
ease, the pathohistological classification of NPC has been
evolving continuously. In 1978, the histological classifica-
tion guideline proposed by the World Health Organization
(WHO) categorized NPC into three groups: type 1 (kera-
tinizing squamous cell carcinoma), type 2 (nonkeratinizing
carcinoma), and type 3 (undifferentiated carcinoma). Types
2 and 3 have also been called lymphoepithelioma [1, 3]. The
1991 WHO classification of nasopharyngeal carcinomas di-
vided them into two groups: squamous cell carcinoma (ker-
atinizing squamous cell carcinoma, type 1 of the former clas-
sification), and nonkeratinizing carcinoma (types 2 and 3 of
the former classification combined under a single category).
The second group (nonkeratinizing carcinoma) was further
subdivided into differentiated and undifferentiated carcino-
mas. Lymphoepithelioma-like carcinoma was considered a
morphologic variant of undifferentiated carcinoma [1]. The
current WHO classification keeps the 1991 terminology, and
adds one additional category: basaloid squamous cell carci-
noma [1, 12].
Published data indicate a probably higher proportion
of keratinizing squamous cell carcinoma among all NPC in
nonendemic areas compared with endemic areas. Some stud-
ies reported that squamous cell carcinoma (former WHO
type 1) accounts for approximately 25% of all NPC in North
America, but only 1% in endemic areas; whereas undifferen-
tiated carcinoma (former WHO type 3) accounts for 95% of
all cases in high incidence areas, but 60% of cases in North
America [1, 3, 12].
1.5. Staging
The extent of the disease is the most important prognos-
tic factor, and staging will have a great impact on the selec-
tion of treatment in patients with NPC [1]. The tumor-node-
metastasis (TNM) staging system, promulgated by the Amer-
ican Joint Comittee on Cancer (AJCC), is the most frequent
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system used to classify the extent of spread of nasopharyn-
geal carcinomas [13]. Information about the tumor, lymph
nodes, and metastasis is combined according to a process
called stage grouping. Each set use Roman numerals O to IV
to describe progression from earliest to most advanced stage.
Therefore, according to this system, patients are designated
into stages 0, I, IIA, IIB, III, IVA, IVB, and IVC [12, 13].
1.6. Diagnosis
NPC shows an extraordinarily high cure rate for early stage
disease, thus early detection is critical to improve the overall
prognosis and reduce morbidity and metastasis [10]. The de-
tection of NPC is based on the clinical history and the phys-
ical examination, but a definitive diagnosis requires a biopsy
of the lesion [3]. A series of radiologic tests, including a com-
puted tomography (CT) scans with intravenous contrast and
magnetic resonance imaging (MRI) of the head and neck are
currently being used to assess the tumor extension and the
stage of the disease [11].
EBV-related antigens in sera are also useful markers for
NPC diagnosis [7, 14]. Ho et al. found an increased diag-
nostic sensitivity and specificity (99% and 96%, resp.) using
a combination of serum protein profiles with an EBV anti-
body serology test [15]. A clinical history of a known metas-
tasis but an unknown site of primary tumor with a positive
serology for EBV may also help in diagnosis, redirecting the
search for a primary disease at the nasopharynx. The plasma
Epstein-Barr virus DNA (EBV-DNA) level has also been sug-
gested to be a reliable indicator for staging and prognosis of
NPC [16]. The EBV infection can also be detected by im-
munostaining of tumoral cells for latent membrane protein
1 (LMP-1), and/or in situ hybridization for EBV-encoded
RNAs. Results using these techniques on paraffin-embedded
tissue sections support the evidence that EBV plays a major
role in the pathogenesis of the disease [17].
1.7. Treatment
External radiotherapy alone is still the primary treatment for
early stage NPC. Concomitant chemoradiotherapy has been
used in recent years for locally advanced disease. The man-
agement of recurrent cervical lymph node metastases in NPC
after radiation and chemotherapy is a radical surgery of the
lymph nodes of the neck with postoperative brachytherapy.
The overall 5-year survival rate for patients with locally ad-
vanced disease is around 55–60%. The salvage surgical proce-
dure for persistent or recurrent neck disease shows a 5-year
control rate of 66% and a 5-year actuarial survival of 38%
[18, 19].
2. GENETIC ANALYSES OF NPC
While nasopharyngeal carcinoma is a rare malignancy in
most parts of the world, it is one of the most common cancers
in Southeast Asia including areas such as southern China,
Hong Kong, Singapore, Malaysia, and Taiwan. The reported
incidence in these countries ranges from 10 to 53 cases per
100,000 persons. The incidence is also high among Eskimos
in Alaska and Greenland and in Tunisians, ranging from 15
to 20 cases per 100,000 persons [2]. A clear and specific eti-
ology for NPC is still lacking. In general, NPC is thought
to be the result of both genetic susceptibility and environ-
mental factors, such as consumption of certain salted food
items [20] and infection with EBV [21]. Familial clustering
of NPC has been widely observed in both the Chinese pop-
ulation [22, 23], and non-Chinese patient cohort [24]. The
familial risk of NPC is among the highest of any malignancy
[25]. The described relative risk of NPC in first-degree rela-
tives is about 8.0 [26, 27]. In this article, we will review the
current progress on genetic analysis of nasopharyngeal car-
cinoma (e.g., genetic susceptibilities and somatic alterations)
in relationship with recent advances in genomic technolo-
gies.
2.1. Progress on searching for genetic
susceptibilities of NPC
Although perhaps not Mendelian, strong evidences suggest
that genetic factors play important roles in NPC. Epidemio-
logical studies suggest that most of the familial aggregation
of NPC derives from inherited susceptibility [2]. A recent
complex segregation analysis on a Chinese cohort provided
additional evidence to support a multifactorial mode of in-
heritance for NPC [28]. However, the molecular genetic ba-
sis of NPC remains unknown. Most of the studies searching
for the susceptibility genes of NPC can be loosely categorized
into 2 methodologies: a positional cloning approach and a
functional cloning approach. A positional cloning approach
aims first to identify the genomic location (or locus) that is
linked to the disease. This is followed by the identification
of the disease gene (or susceptibility gene) at this particu-
lar genomic location. The functional cloning approach, also
known as candidate gene-based approach, requires sufficient
prior knowledge of the disease and the functional defect(s)
associated with the disease. Candidate gene(s) are identified
based on this knowledge. Mutations (or polymorphisms) will
then be identified and investigated in the candidate gene.
These approaches complement each other. Positional cloning
approaches can lead to identification of a candidate gene for
functional cloning studies. On the other hand, a functional
cloning approach often confirms the genomic location of
the susceptibility locus identified by positional cloning stud-
ies. The following sections will summarize the progress of
identifying the NPC susceptibility genes based on these ap-
proaches.
2.1.1. Positional cloning approach searching for
NPC susceptibility genes
Linkage analyses are the most common approaches for the
identification of a disease locus (or susceptibility locus).
There are several variations of linkage analysis design, based
on the pedigree structure. The linkage studies usually involve
genotyping of both affected individuals and healthy family
members using a panel of genetic markers. Most of the link-
age studies on NPC performed so far have used microsatel-
lite markers that are essentially polymorphic tandem repeats
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of di- to tetranucleotide sequence motifs flanked by unique
sequences. This approach is usually tedious, labor-intensive,
and requires large amounts of sample DNA, allowing only a
modest number of markers to be screened. However, the re-
cent completion of the human genome project has lead to
the identification of millions of single nucleotide polymor-
phisms (SNP), the most abundant type of polymorphism in
the human genome, which will lead to another wave of in-
tense search for the NPC susceptibility locus/gene.
Several linkage analyses studies suggested the associa-
tion of susceptibility HLA haplotypes with NPC develop-
ment. Most studies conducted among the Chinese popula-
tion demonstrated an increased risk of NPC for individuals
with HLA-A2. A recent study detected a consistent associa-
tion between NPC and the prevalent Chinese HLA-A2 sub-
type (HLA-A∗0207), but not the prevalent Caucasian sub-
type (HLA-A∗0201) [29]. The HLA types of AW19, BW46,
and B17 have also been reported to be associated with an in-
creased risk, whereas HLA-A11 is associated with a decreased
risk [30]. The involvement of HLA in NPC tumorigenesis
may be through its cytotoxic T cell recognition and host im-
mune response to EBV infection. However, it has been sus-
pected that HLA alleles may not directly contribute to the
susceptibility of NPC. Interestingly, Lu et al. (1990) reported
a linkage study based on affected sib pairs which suggested
that a gene closely linked to the major histocompatibility
complex (MHC) region but distinct from the HLA genes
confers a greatly increased risk of nasopharyngeal carcinoma
[31].
A recent study provides evidence for the linkage of NPC
to chromosome 3p and a fine map of NPC susceptibility
locus to a 13.6-cM region on 3p21.31-21.2 [32]. These re-
sults are in agreement with several previous studies that sug-
gest that the deletion of chromosomes 3p is a common ge-
netic event in NPC [33, 34]. Many tumor suppressor candi-
date genes such as CACNA2D2, DLC1, FUS1, H37, HYAL1,
RASSF1A, SEMA3B, and SEMA3F and tumor susceptibility
genes such as hMLH1 have been isolated from the region
[32]. These studies indicate that genes in the 3p21 may play
a critical role in tumorigenesis of familial NPC. Consistent
with this notion, another study detected a high frequency
of loss of heterozygosity on 3p, in histologically normal na-
sopharyngeal epithelia and dysplastic lesions from Southern
Chinese individuals, suggesting that the genetic abnormal-
ity appear to be causative for NPC [35]. Isolation and iden-
tification of susceptibility genes from 3p21 may greatly ad-
vance the understanding of the etiology and development of
NPC.
A recent genome-wide scanning of 20 families with in-
cluded 65 affected individuals provides evidence of a ma-
jor susceptibility locus for NPC on chromosome 4p15.1-
q12 [36]. The strongest linkage was observed with marker
D4S405 (LOD score = 3.54) and D4S3002 (LOD score = 4.2).
Interestingly, when EBV antibody titer was included as a co-
variate, the LOD scores reached 4.70 and 5.36 for these mark-
ers, respectively. This observation was recently confirmed by
a population-based large-scale study of Han Chinese from
Guangxi province using 34 microsatellites spanning an 18-
megabase region of chromosome 4 (4p15.1-q12) [37].
2.1.2. Functional cloning approach searching for
NPC susceptibility genes
Recent studies suggested that genetic polymorphisms in
genes that metabolize carcinogens are associated with NPC
susceptibility. Cytochrome P450 2E1 (CYP2E1) is one of the
cytochrome P450s and is responsible for the metabolic acti-
vation of nitrosamines and the related carcinogens. The vari-
ant form of CYP2E1 has a marked difference in its activity
and causes different levels of DNA damage in human cells.
Nitrosamines are the effective carcinogens for NPC and are
believed to be involved in the pathogenesis of NPC. Case-
control studies have shown a strong association of the vari-
ant form of CYP2E1 (c2 allele) with increased risk of this dis-
ease in Chinese populations [38, 39]. Other nitrosamine me-
tabolizing genes, such as Cytochrome P450 2A6 (CYP2A6),
have also been suggested to play a role in NPC susceptibility
[40].
Genetic polymorphism of glutathione S-transferase M1
(GSTM1) is a phase II enzyme known to play an impor-
tant role in the detoxification of several carcinogens found
in tobacco smoke, a synergistic risk factor for NPC [41].
This enzyme also modulates the induction of other en-
zymes and proteins that are important for cellular func-
tions, such as DNA repair. The enzyme is therefore im-
portant to metabolize carcinogens, maintaining genomic
integrity and cancer susceptibility. A recent study in the
United States has reported that GSTM1 null genotype is as-
sociated with an almost twofold increase in risk for NPC
[42]. The findings implied that polymorphisms of this
modifier might lead to different cellular responses to en-
vironmental carcinogens among different individuals, dif-
ferent degrees of genetic instability or damages in the na-
sopharyngeal epithelial cells. Similar associations were ob-
served in studies on Tunisian and Thai populations [43,
44].
The association of other DNA repair genes with NPC sus-
ceptibility has also been implied. Both X-ray repair cross-
complementing group 1 gene (XRCC1) and 8-oxoguanine
glycosylase 1 (hOGG1) are important in DNA base exci-
sion repair. While a reduced risk for NPC was observed
with polymorphism of the XRCC1 gene (Arg280His), poly-
morphism of the hOGG1 gene (Ser326Cys) was shown to
be associated with an increased risk for NPC in the Tai-
wan population [45]. The reduced risk of NPC associated
with polymorphism in the XRCC1 gene was confirmed with
a different polymorphism (Arg194Trp) recently identified
in the population from Guangdong, China, particularly in
males and smokers [46]. Interestingly, the higher risk of
NPC was observed among those subjects with certain com-
bined genotypes for both hOGG1 and XRCC1 polymor-
phisms [45], clearly suggesting that carriers of multiple pu-
tative high-risk genotypes have the highest risk of developing
NPC.
The potential roles of genes that contribute to the im-
mune response have also been studied. Signaling pathways
activated by the toll-like receptor 4 (TLR4) involve the induc-
tion of anticancer immunity. Functional analyses of an SNP
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variant of the TLR4 gene at the 3′-untranslated region (3′-
UTR) suggested that it is associated with decreased mRNA
stability, and leads to a reduced expression of this gene [47].
This 3′-UTR polymorphism has been shown to be associ-
ated with a significantly increased risk for NPC. It is hy-
pothesized that this polymorphism downregulates TLR4 ex-
pression through destabilizing the mRNA, and leads in EBV
metainfective antiviral immunologic deficits and a high risk
of NPC. Similarly, associations with increased risks for NPC
have also been detected with polymorphism in toll-like re-
ceptor 1, 6, 10, respectively [23, 48].
The palate, lung, and nasal epithelium carcinoma-
associated (PLUNC) protein gene plays a role in the innate
immune response in the regions of the oral and nasal cavi-
ties. In a recent case-controlled study of Chinese population
composed of 239 unrelated NPC patients and 286 healthy
controls, SNPs in the promoter region of this gene (PLUNC)
were significantly associated with susceptibility to NPC, [49].
These results suggest that genetic variation in PLUNC may
influence susceptibility to NPC in this Chinese population.
Tremendous enthusiasm in the genetics community has
been generated for the identification of millions of poly-
morphisms (e.g., SNPs) throughout the human genome.
Recently, an increasing number of studies have been de-
voted to investigate the polymorphisms in a variety of
cancer-related genes for their potential influence on NPC
susceptibility, including matrix metalloproteinases (MMPs)
[50, 51], transforming growth factor-beta1 (TGF-beta1)
[52], interleukin-10 (IL-10) [53], antigen processing 1 gene
(TAP1) [54], p53 [55], cyclin D1 (CCND1) [56], FAS
(CD95) [57], mouse double minute 2 (MDM2) [58], and
Nedd4 binding protein 2 (N4BP2) [59]. While polymor-
phisms in these genes have been associated with a statisti-
cally significantly increased risk of NPC, the risks are gen-
erally small and appear to be restricted to specific stud-
ies. It is apparent that the understanding of interactions of
these polymorphisms and other risk factors are more im-
portant. With the continuous advances in high-throughput
sequence and genotyping technologies, this list will increase
rapidly.
SNPs appear to be the most abundant sequence varia-
tions between individuals. Enthusiasm for very high density
SNP sets in the human genome has been largely centered
on the potential use for association studies, especially in the
context of measured linkage disequilibrium. Indeed, success-
ful implementations using genome-wide association analysis
have already been reported for cancer risks [60, 61]. A re-
cent milestone publication by the Welcome Trust Case Con-
trol Consortium [62] established the “standard” for genome-
wide association analysis, in term of result interpretation,
quality control, population stratification, and control sample
sharing. These advances in analytical approaches, together
with the advent of rapid, affordable, large-scale genotyping
methods that enable the cotyping of over 500,000 SNPs on
each genomic sample (http://www.affymetrix.com), greatly
facilitate the search for new susceptibility genes of NPC, and
will lead to a better understanding of the potential interac-
tions among susceptibility genes and between susceptibility
genes and environmental factors.
2.2. Progress on profiling somatic abnormalities of
the NPC genome
Tumors develop through the combined processes of genetic
instability and selection, resulting in clonal expansion of cells
that have accumulated the most advantageous set of genetic
aberrations. Many types of instability can contribute to neo-
plastic development, including point mutations, chromoso-
mal rearrangements, DNA dosage abnormalities (amplifica-
tions or deletions), alteration of microsatellite sequences, and
epigenetic changes. Knowledge of genomic aberrations can
have clinical implications in diagnosis, treatment, and prog-
nostics of cancer. Four decades ago, the milestone discovery
of Philadelphia chromosome (a translocation between chro-
mosome 9 and 22, which fuses the Bcr gene and the Abl ty-
rosine kinase gene) [63] led to one of the first effective tar-
geted therapies for cancer: treatment of chronic myelogenous
leukemia (CML) with the tyrosine kinase inhibitor imatinib
(Gleevec). Since then, many exciting clinical advances have
been made based on the increasing knowledge of the tumor
genome.
During the 1970s and 1980s, several genome-wide ap-
proaches were developed to measure these tumor genomic
alterations including loss of heterozygosity analysis (LOH)
and comparative genomic hybridization (CGH). Advances
in genetics and bioengineering have refined these techniques
over the past two decades, and the recent development of
multicolor staining-based cytogenetic techniques such as
multicolor fluorescence in situ hybridization (M-FISH) and
spectral karyotyping (SKY) have further improved the ability
to analyze the tumor genome [64]. The completion of the hu-
man genome project [65, 66] now makes it possible to query
the cancer genome systematically in ways that were hith-
erto impossible. Microarrays designed to analyze targeted
genomic regions relevant to chronic lymphocytic leukemia
have been produced for use in clinical trials to determine the
relationship between therapeutic options and genomic aber-
rations [67]. Association of genomic aberrations with prog-
nosis has been found for a variety of tumor types, including
prostate cancer [68], breast cancer [69], gastric cancer [70],
head and neck cancer [71], lymphoma [72, 73], and NPC
[74].
2.2.1. Progress on genomic profiling of NPC
Copy number analysis of NPC
Comparative genomic hybridization (CGH) was developed
to survey gene copy number abnormalities (amplifications
and deletions) across a whole genome [75]. In a typical CGH
analysis, fluorescently labeled disease DNA (frequently Fluo-
rescein or FITC) and normal DNA (frequently Rhodamine or
Texas Red) are cohybridized to the normal metaphase chro-
mosomes to generate fluorescence ratios along the length
of chromosomes that provide a cytogenetic representation
of DNA copy number variation. CGH was the first effec-
tive approach to scanning the entire genome for variations in
DNA content [76, 77]. A large number of CGH-based stud-
ies on NPC lead to the identification of consistent gain at
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chromosome 1q, 3q, 8q, 12 and loss at 3p, 9p, 11q, 14q [78–
81]. A recent large-scale meta-analysis of CGH results re-
vealed several genomic “hotspots” that show consistent copy
number alterations in NPC [82]. These findings provided
foundation for further identifications of the corresponding
oncogenes and tumor suppressor genes in NPC.
While chromosome-based CGH provided critical hints
for identifying candidate genes for NPC, it has a limited map-
ping resolution (∼20 Mb). Array-based CGH is a second-
generation approach in which fluorescence ratios on mi-
croarrayed DNA elements provide a locus-by-locus measure
of gene copy number variation [83, 84]. Using this approach,
frequent amplifications were detected for several oncogene
loci, including MYCL1 at 1p34.3 (66.7%), TERC at 3q26.3
(46.7%), ESR at 6q25.1 (46.7%), and PIK3CA at 3q26.3
(40%) [85].
Although the array-based CGH can potentially increase
mapping resolution, most of the early arrays used for the
CGH studies have utilized large genomic clones, for exam-
ple, bacterial artificial chromosomes (BACs), which have a
limited spatial sensitivity. In addition, large genomic clones
also suffer from reduced specificity due to their inclusion of
common repeats (e.g., Alu and long interspersed nuclear el-
ements (LINEs)), redundant sequences (e.g., low copy re-
peats (LCRs), also known as segmental duplications), and
segments of extensive sequence similarity (pseudogenes or
paralogous genes) [86]. Recently, several additional higher-
density tools for CGH analysis have become available with
the completion of the human genome sequence. These in-
clude cDNA array-based CGH [87, 88], oligonucleotide
array-based CGH [89, 90], tiling array-based CGH [84], and
copy number analysis using high-density SNP microarrays
[91–94]. Tiling and SNP array-based approaches have drawn
most attention due to their high resolution. Tiling arrays
have the potential to resolve small (gene level) gains and
losses (resolution ∼40 kb) that might be missed by marker-
based genomic arrays which contain large number of gaps
due to the distance between the targeted probes [84, 95]. We
can envision that in the near future, we will have the ability
to survey copy number changes at close to bp resolution us-
ing tiling arrays that contain billions of overlapping probes
covering the entire genome. The SNP array-based approach
provides the unique advantage of concurrent CGH and LOH
analysis, which we discuss in further detail below [92, 93].
Loss of heterozygosity (LOH) analysis of NPC
Chromosomal aberrations include segments of allelic imbal-
ance identifiable by loss of heterozygosity (LOH) at poly-
morphic loci, which can be used to identify regions harbor-
ing tumor suppressor genes. Allelic losses, which are caused
by mitotic recombination, gene conversion, or nondisjunc-
tion cannot be detected by CGH and thus require LOH anal-
ysis for their identification. This approach is “favored” by
the Knudson two-hit hypothesis [96, 97] for hunting the
tumor-suppressor genes. Traditionally, polymorphic mark-
ers, such as restriction fragment length polymorphisms
(RFLPs) and microsatellite markers, have been used to de-
tect LOH through allelotypic comparisons of DNA from a
cancer sample and a matched normal sample [98]. However,
this approach is time consuming, and labor intensive, and re-
quires a large amount of sample DNA, allowing only a mod-
est number of markers to be screened. Most of the early LOH
studies were focused on individual chromosomes, and only
a few genome-wide LOH studies have been performed on
NPC [34, 99–101]. The most frequent LOH were observed
at chromosome 3p, 9p, and 14q, which is in agreement with
the CGH based findings.
The mapping of the human genome has allowed for
the identification of millions of SNP loci (http://www.ncbi
.nlm.nih.gov/SNP), which makes them ideal markers for var-
ious genetic analyses, including LOH. Because of their abun-
dance, even spacing, and stability across the genome, SNPs
have significant advantages over RFLPs and microsatellite
markers as a basis for high-resolution whole genome al-
lelotyping with accurate copy number measurements. High-
density oligonucleotide arrays have recently been generated
to support large-scale high throughput SNP analysis [102].
It is now possible to genotype over 500,000 SNP markers us-
ing the Affymetrix Mapping 500K SNP oligonucleotide array.
LOH patterns generated by SNP array analysis have a high
degree of concordance with previous microsatellite analy-
ses on the same cancer samples [103]. Additionally, shared
regions of LOH from SNP arrays can cluster lung cancer
samples into subtypes [104], and distinct patterns of LOH
are found to associate with specific clinical features in pri-
mary breast, bladder, head and neck, and prostate tumors
[93, 105–108]. While SNP array has not been utilized in NPC
studies, it is expected that large scale SNP array-based LOH
profiles will be generated on NPC in the near future. It is
worth noting that a high-density SNP array is also a very
powerful tool for identifying susceptibility gene(s) using ei-
ther linkage or association study designs. One might envi-
sion that with a single high-throughput genomic platform,
large-scale population-based study, searching for genetic sus-
ceptibility of NPC (inherited risk factors) can be performed
concurrently with genomic profiling of NPC (somatic muta-
tions).
Cytogenetic analysis of NPC
Cytogenetics has be widely used since the introduction
of chromosome-banding techniques (keryotyping) in 1969
[109, 110]. One major drawback of these approaches is the
requirement of in vitro culture and metaphase preparation of
the cells of interest. Due to the poor tumor growth in vitro,
only a limited number of karyotyping-based studies have
been performed on primary NPC, which suggested genomic
aberrations of 3q and 5q [111, 112]. Nevertheless, cytoge-
netic approaches will always have their place in the genomic
profiling due to the ability to directly visualize chromoso-
mal abnormalities. To obtain the cytogenetic information,
cell lines and xenografts have been used frequently for the
karyotyping studies on NPC, where many structural and nu-
merical alterations found on 1p, 3p, 3q, 5q, 9p, 12, 11q, 13q,
14q, 16q, and X [113–118]. Among these alterations, deletion
of 3p and gain of 3q are the most frequent events [119, 120].
More importantly, these cytogenetic techniques complement
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Table 1: The most frequent genomic abnormalities of NPC.
Frequent abnormalities
CGH Gain: 1q, 3q, 8q, 12p, 12q and
loss: 3p, 9p, 11q, 14q, 16q
LOH 3p, 9p, and 14q,
Karyotyping Gain: 3q and loss: 3q
CGH and LOH by providing information on chromosomal
structural rearrangements that are not resolved by DNA copy
number analyses. For example, balanced translocations are
one of the more common genomic abnormalities in cancer
[121], but they cannot be detected by CGH or LOH. An ex-
perienced cytogeneticist, however, can readily detect many
forms of chromosomal rearrangements of NPC using classi-
cal cytogenetic techniques, such as karyotyping [122].
The advances in the labeling techniques lead to the devel-
opment of fluorescence in situ hybridization (FISH) method,
which has proven to be an excellent choice for indepen-
dent validation of other genomic methods. Fan et al. [123]
reported FISH-based studies to validate the frequent am-
plification of c-myc and Int-2 that was initially discovered
by CGH analysis. Recently, with the introduction of several
new labeling techniques, such as spectral karyotyping (SKY),
multicolor FISH (M-FISH), cross-species color banding (Rx-
FISH), and multicolor chromosome banding, it is possible
to carry out discovery studies using the cytogenetic meth-
ods. These techniques permit the simultaneous visualization
of all chromosomes in different colors, and thus consider-
ably improve the detection of translocations or deletions.
For example, both SKY and M-FISH use a combinatorial la-
beling scheme with spectrally distinguishable fluorochromes.
The chromosome-specific probe pools (chromosome paint-
ing probes) are generated from flow-sorted chromosomes
and then amplified and fluorescently labeled by degener-
ate oligonucleotide-primed polymerase chain reaction. With
the introduction of these techniques in 1996 [124–126], the
comprehensive analysis of complex chromosomal rearrange-
ments present in tumor karyotypes was greatly improved. A
recent SKY analysis on NPC cell lines confirmed most of the
abnormalities identified previously by CGH and LOH and il-
lustrated additional breakpoints on a number of apparently
balanced chromosomes, including 3p21, 3q26, 5q31, 6p21-
p25, 7p14-p22 and 8q22 [127].
2.2.2. Genome-wide expressional microarray
analysis of NPC
The use of microarray and other global profiling technolo-
gies has led to a significant number of exciting new biolog-
ical discoveries, and important correlations between gene-
expression patterns and disease states. Never before could a
small sample of RNA from two different conditions reveal so
much information at the transcriptional level. Microarray-
based expression profiling on tumor tissues have been used
to identify molecular signatures that can promote the pre-
cise classification and prognostication of various types of
cancers. Historically, only a few expression profiling analysis
studies have been performed on NPC [128–130]. The lim-
ited amount of available clinical materials and heavy infiltra-
tion of non-cancer cells present major difficulties for these
studies. With advances in preamplification technologies and
microdissection tools, comprehensive expression profiling of
NPC is possible. In the past couple of years, several genome-
wide expression profiling studies have been devoted to iden-
tify candidate genes (e.g., genes involved in regulations of Ras
activity, cell cycle, and WNT pathway) [131, 132], investigate
the disease etiology (e.g., EBV infection, host responses, and
hypoxia) [133–135], and evaluate the therapeutic effective-
ness on NPC [136]. With the continuation of advances in
genome-wide expressional microarray technology, compre-
hensive expression profiling of NPC is now starting to take
the center stage. This should lead to substantial translational
outcomes that will advance the management of this disease.
2.2.3. Comprehensive genomic approaches
A major challenge confronting the identification of the
molecular genetic factors that contribute to the NPC tu-
morigenesis is the diversity of the genetic alterations. Among
these are germline variations (such as the susceptibility genes
described in previous section) that lead to hereditary can-
cer predispositions, the acquisition of transforming DNA or
RNA sequences from cancer viruses (e.g., EBV for NPC),
somatic mutations in the cancer genome (e.g., copy num-
ber change, translocation, LOH), and epigenetic mechanisms
(such as DNA methylation or histone modification) that pro-
mote oncogenesis by modifying cancer-related genes. So-
matic genomic alterations such as point mutations, genomic
amplifications or deletions, loss of allelic heterozygosity, and
chromosomal translocations are believed to play a central
role in the development of most solid tumors, including
NPC. All of these mechanisms result in dysregulated expres-
sion of oncogenes and tumor suppressor genes, but none of
the existing genomic techniques can capture all of these ge-
netic changes in a single analysis (see Figure 2). This repre-
sents a major obstacle to the comprehensive analysis of tu-
mor genomes and their relationship to clinical phenotypes
or disease progression.
A more practical approach to overcome this problem is
to combine a selective set of molecular genetic technolo-
gies such as CGH, LOH, and various molecular cytogenetic
analyses for comprehensive screening of genomic alterations
with high resolution. Each of these techniques has their own
unique advantages, but they also have their own limitations
which have motivated efforts to combine these approaches
as shown in Figure 2. In this instance, the SNP array-based
LOH and CGH analyses provide a high-resolution mapping
of copy number abnormalities, but offer little information on
chromosomal structure/spatial changes (e.g., translocations,
the most common class of somatic mutation registered in
the cancer gene census [121]). On the other hand, modern
cytogenetic techniques provide a clear picture of the gross
chromosomal structure/spatial alterations, but have limited
resolution. Therefore, strategically combining a complemen-
tary set of genetic tests is a logical approach for character-
izing a complex cancer genome. This has been successfully
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Figure 2: Identification of chromosomal abnormalities using various genomic and cytogenetic approaches. “+” and “−” denote effectiveness
and ineffectiveness of the methods for the detection of a specific chromosomal abnormality. Banding: chromosome banding or karyotyping
analysis; SKY: spectral karyotyping analysis; M-FISH: multicolor fluorescence in situ hybridization; CGH: comparative genomic hybridiza-
tion; DK: digital karyotyping analysis; LOH: loss of heterozygosity. Adapted from [137] with kind permission of Future Drugs Ltd.
attempted to investigate the immortalization of nasopha-
ryngeal epithelial cells [138], where karyotyping, spectral
karyotyping (SKY) and array CGH were utilized concur-
rently to reveal a gain of 17q21–q25 fragment on 11p15
chromosome, with the specific derivative chromosome 11:
der(11)t(11;17)(p15.1;q21.1).
This multimodal approach can be extended to combine
DNA structural analyses with additional genome functional
activity at the RNA and/or protein levels. Recent technical
advances in microarray-based gene expression analysis have
offered substantial improvement in diagnosis, treatment, and
prognosis of cancer patients. This continuous progress in
microarray-based expression analysis and the large public
depositories of microarray data have motivated new efforts
to extract additional biological information from these data
in addition to the static RNA transcript levels. One such at-
tempt involves inferring the chromosomal structural changes
from spatially-linked changes in microarray expression data
[139–142]. Several array CGH studies have shown a genome-
wide correlation of gene expression with copy number al-
terations and have proved useful in individual amplicon re-
finement [143, 144]. For example, through tissue microar-
ray FISH and RT-PCR, a minimally amplified region around
ERBB2 was identified in a large number of breast tumors.
In addition, gene amplification was found to be correlated
with increased gene expression in a subset of those samples
[145]. Recently, several groups have observed that chromo-
somal alterations can lead to regional gene expression bi-
ases in human tumors and tumor-derived cell lines [139–
141, 146, 147]. A recent study also demonstrated the cor-
relation between SNP array-based LOH profiles and expres-
sion profiles [105]. These studies suggest that a fraction of
gene expression values (15–25%) are regulated in concor-
dance with chromosomal DNA content [139–141, 146, 147].
Several statistical methods have been developed and have
shown promising results for detecting DNA copy number ab-
normalities based on differential gene expression [139–142].
With the recent growth in transcriptomic profiling studies
of NPC, these techniques for “reverse inference” of DNA
alterations from RNA expression data will become a valu-
able approach for genomic profiling that can provide cross-
validation of functional genomic alterations at multiple bio-
logical levels when combined with DNA-based approaches
such as CGH and LOH. These attempts for strategic inte-
gration of genomic information at multiple levels provide
an exciting paradigm to introduce the system biology (or
more specifically system genomics) concept into NPC re-
search. Further strategies for implementing a comprehensive
database that contains additional levels of genomic informa-
tion such as alternative splicing and methylation status have
also been suggested.
3. FUTURE DIRECTIONS
The high susceptibility of individuals in Southern Asia to
NPC is still puzzling. The recent advances in the single
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nucleotide polymorphism and haplotype analyses, genome-
wide screening, and association studies may help to decipher
the inheritable genetic components for this enigmatic can-
cer. The cellular genes involved in DNA damage and its as-
sociation with EBV entry or latency should be focused upon
and further explored. Recently deployed technologies, such
as high-density SNP array, will play a critical role in the
search of these susceptibility genes. This same platform has
also been successfully adapted to perform LOH and CGH
profiling of the cancer genome, which place it in a unique
position in the area of NPC research.
Previous molecular studies on NPC have focused on
DNA and chromosomal levels, but few on transcriptomic
and proteomic profiles. Small biopsy material and heavy in-
filtration of non-cancer cells present major difficulties for
transcriptomic and proteomic studies. With advances in mi-
crodissection and preamplification technology, comprehen-
sive expression profiling of NPC is now starting to take center
stage. This should lead to substantial translational outcomes
that will advance the management of this disease.
While substantial amount of information on the ge-
nomic alteration of NPC have been accumulated, the recent
advances in genomic technologies (e.g., high-density SNP
array) and the vast resources created by Human Genome
Project will lead to more comprehensive results. Strategic in-
tegration of the data streams from multiple experimental ap-
plications (e.g., CGH, LOH, and expression microarray) at
different biological levels (e.g., DNA, RNA and protein lev-
els) will greatly enhance our ability to capture the precise
portrait of the NPC genome.
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